Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems.

Gardiner BJ, Stewardson AJ, Abbott IJ, Peleg AY.

Aust Prescr. 2019 Feb;42(1):14-19. doi: 10.18773/austprescr.2019.002. Epub 2019 Feb 1. Review. No abstract available.

2.

Fatal disseminated visceral Varicella Zoster Virus infection in a renal transplant recipient.

Loftus MJ, Yong MK, Wilson S, Peleg AY.

Transpl Infect Dis. 2019 Feb 12:e13062. doi: 10.1111/tid.13062. [Epub ahead of print]

PMID:
30756453
3.

Characterization of hypermutator Pseudomonas aeruginosa isolates from patients with cystic fibrosis in Australia.

Rees VE, Deveson Lucas DS, López-Causapé C, Huang Y, Kotsimbos T, Bulitta JB, Rees MC, Barugahare A, Peleg AY, Nation RL, Oliver A, Boyce JD, Landersdorfer CB.

Antimicrob Agents Chemother. 2019 Feb 11. pii: AAC.02538-18. doi: 10.1128/AAC.02538-18. [Epub ahead of print]

PMID:
30745381
4.

Identification of Novel Acinetobacter baumannii Host Fatty Acid Stress Adaptation Strategies.

Jiang JH, Hassan KA, Begg SL, Rupasinghe TWT, Naidu V, Pederick VG, Khorvash M, Whittall JJ, Paton JC, Paulsen IT, McDevitt CA, Peleg AY, Eijkelkamp BA.

MBio. 2019 Feb 5;10(1). pii: e02056-18. doi: 10.1128/mBio.02056-18.

5.

Evolution of daptomycin resistance in coagulase negative staphylococci involves mutations of the essential two component regulator WalKR.

Jiang JH, Dexter C, Cameron DR, Monk IR, Baines S, Abbott IJ, Spelman DW, Kostoulias X, Nethercott C, Howden BP, Peleg AY.

Antimicrob Agents Chemother. 2019 Jan 7. pii: AAC.01926-18. doi: 10.1128/AAC.01926-18. [Epub ahead of print]

PMID:
30617095
6.

OXA-23 Is a Prevalent Mechanism Contributing to Sulbactam Resistance in Diverse Acinetobacter baumannii Clinical Strains.

Yang Y, Xu Q, Li T, Fu Y, Shi Y, Lan P, Zhao D, Chen Q, Zhou Z, Jiang Y, Peleg AY, Yu Y.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01676-18. doi: 10.1128/AAC.01676-18. Print 2019 Jan. No abstract available.

PMID:
30348663
7.

A Randomized Study of Quantiferon-CMV-Directed Versus Fixed Duration Valganciclovir Prophylaxis to Reduce Late CMV Following Lung Transplantation.

Westall GP, Cristiano Y, Levvey BJ, Whitford H, Paraskeva MA, Paul E, Peleg AY, Snell GI.

Transplantation. 2018 Sep 21. doi: 10.1097/TP.0000000000002454. [Epub ahead of print]

PMID:
30247316
8.

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.

Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN).

JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163.

PMID:
30208454
9.

Comprehensive antibiotic-linked mutation assessment by resistance mutation sequencing (RM-seq).

Guérillot R, Li L, Baines S, Howden B, Schultz MB, Seemann T, Monk I, Pidot SJ, Gao W, Giulieri S, Gonçalves da Silva A, D'Agata A, Tomita T, Peleg AY, Stinear TP, Howden BP.

Genome Med. 2018 Aug 31;10(1):63. doi: 10.1186/s13073-018-0572-z.

10.

Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.

Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01150-18. doi: 10.1128/AAC.01150-18. Print 2018 Nov.

PMID:
30104278
11.

Spectrum of illness among returned Australian travellers from Bali, Indonesia: a 5-year retrospective observational study.

Sohail A, McGuinness SL, Lightowler R, Leder K, Jomon B, Bain CA, Peleg AY.

Intern Med J. 2019 Jan;49(1):34-40. doi: 10.1111/imj.13993.

PMID:
29869360
12.

In vivo atomic force microscopy-infrared spectroscopy of bacteria.

Kochan K, Perez-Guaita D, Pissang J, Jiang JH, Peleg AY, McNaughton D, Heraud P, Wood BR.

J R Soc Interface. 2018 Mar;15(140). pii: 20180115. doi: 10.1098/rsif.2018.0115.

PMID:
29593091
13.

Evolution of carbapenem resistance in Acinetobacter baumannii during a prolonged infection.

Hawkey J, Ascher DB, Judd LM, Wick RR, Kostoulias X, Cleland H, Spelman DW, Padiglione A, Peleg AY, Holt KE.

Microb Genom. 2018 Mar 16. doi: 10.1099/mgen.0.000165. [Epub ahead of print]

14.

Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model.

Bilal H, Peleg AY, McIntosh MP, Styles IK, Hirsch EB, Landersdorfer CB, Bergen PJ.

J Antimicrob Chemother. 2018 Jun 1;73(6):1570-1578. doi: 10.1093/jac/dky045.

PMID:
29506207
15.

Mobile phones and computer keyboards: unlikely reservoirs of multidrug-resistant organisms in the tertiary intensive care unit.

Smibert OC, Aung AK, Woolnough E, Carter GP, Schultz MB, Howden BP, Seemann T, Spelman D, McGloughlin S, Peleg AY.

J Hosp Infect. 2018 Jul;99(3):295-298. doi: 10.1016/j.jhin.2018.02.013. Epub 2018 Mar 2.

PMID:
29501730
16.

Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.

Landersdorfer CB, Rees VE, Yadav R, Rogers KE, Kim TH, Bergen PJ, Cheah SE, Boyce JD, Peleg AY, Oliver A, Shin BS, Nation RL, Bulitta JB.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02055-17. doi: 10.1128/AAC.02055-17. Print 2018 Apr.

17.

Convergent Evolution Driven by Rifampin Exacerbates the Global Burden of Drug-Resistant Staphylococcus aureus.

Guérillot R, Gonçalves da Silva A, Monk I, Giulieri S, Tomita T, Alison E, Porter J, Pidot S, Gao W, Peleg AY, Seemann T, Stinear TP, Howden BP.

mSphere. 2018 Jan 24;3(1). pii: e00550-17. doi: 10.1128/mSphere.00550-17. eCollection 2018 Jan-Feb.

18.

Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model.

Abbott IJ, Meletiadis J, Belghanch I, Wijma RA, Kanioura L, Roberts JA, Peleg AY, Mouton JW.

J Antimicrob Chemother. 2018 Mar 1;73(3):709-719. doi: 10.1093/jac/dkx441.

PMID:
29253153
19.

Donor-Derived Mycoplasma hominis and an Apparent Cluster of M. hominis Cases in Solid Organ Transplant Recipients.

Smibert OC, Wilson HL, Sohail A, Narayanasamy S, Schultz MB, Ballard SA, Kwong JC, de Boer J, Morrissey CO, Peleg AY, Snell GI, Paraskeva MA, Jenney AWJ.

Clin Infect Dis. 2017 Oct 16;65(9):1504-1508. doi: 10.1093/cid/cix601.

PMID:
29048510
20.

Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.

Peleg AY, Choo JM, Langan KM, Edgeworth D, Keating D, Wilson J, Rogers GB, Kotsimbos T.

J Cyst Fibros. 2018 Jan;17(1):50-56. doi: 10.1016/j.jcf.2017.08.002. Epub 2017 Oct 15.

PMID:
29042177
21.

Synthesis of novel 1,2,5-oxadiazoles and evaluation of action against Acinetobacter baumannii.

Christoff RM, Murray GL, Kostoulias XP, Peleg AY, Abbott BM.

Bioorg Med Chem. 2017 Dec 15;25(24):6267-6272. doi: 10.1016/j.bmc.2017.08.015. Epub 2017 Aug 10.

PMID:
29032931
22.

Structural Basis for Linezolid Binding Site Rearrangement in the Staphylococcus aureus Ribosome.

Belousoff MJ, Eyal Z, Radjainia M, Ahmed T, Bamert RS, Matzov D, Bashan A, Zimmerman E, Mishra S, Cameron D, Elmlund H, Peleg AY, Bhushan S, Lithgow T, Yonath A.

MBio. 2017 May 9;8(3). pii: e00395-17. doi: 10.1128/mBio.00395-17.

23.

Vancomycin-intermediate Staphylococcus aureus isolates are attenuated for virulence when compared with susceptible progenitors.

Cameron DR, Lin YH, Trouillet-Assant S, Tafani V, Kostoulias X, Mouhtouris E, Skinner N, Visvanathan K, Baines SL, Howden B, Monk IR, Laurent F, Stinear TP, Howden BP, Peleg AY.

Clin Microbiol Infect. 2017 Oct;23(10):767-773. doi: 10.1016/j.cmi.2017.03.027. Epub 2017 Apr 7.

24.

Global Gene Expression Profile of Acinetobacter baumannii During Bacteremia.

Murray GL, Tsyganov K, Kostoulias XP, Bulach DM, Powell D, Creek DJ, Boyce JD, Paulsen IT, Peleg AY.

J Infect Dis. 2017 Feb 15;215(suppl_1):S52-S57. doi: 10.1093/infdis/jiw529.

PMID:
28375520
25.

Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition.

Harris PNA, McNamara JF, Lye DC, Davis JS, Bernard L, Cheng AC, Doi Y, Fowler VG Jr, Kaye KS, Leibovici L, Lipman J, Llewelyn MJ, Munoz-Price S, Paul M, Peleg AY, Rodríguez-Baño J, Rogers BA, Seifert H, Thamlikitkul V, Thwaites G, Tong SYC, Turnidge J, Utili R, Webb SAR, Paterson DL.

Clin Microbiol Infect. 2017 Aug;23(8):533-541. doi: 10.1016/j.cmi.2016.10.023. Epub 2016 Nov 1. Review.

26.

Polymicrobial infections involving clinically relevant Gram-negative bacteria and fungi.

Dhamgaye S, Qu Y, Peleg AY.

Cell Microbiol. 2016 Dec;18(12):1716-1722. doi: 10.1111/cmi.12674. Epub 2016 Oct 20. Review.

PMID:
27665610
27.

Optimizing Microplate Biofilm Assays to Screen Anti-infective Surfaces.

Qu Y, Thissen H, McGiffin D, Peleg AY.

Trends Biotechnol. 2017 Jan;35(1):3-5. doi: 10.1016/j.tibtech.2016.09.001. Epub 2016 Sep 23. No abstract available.

PMID:
27666729
28.
29.

Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.

Jeong W, Haywood P, Shanmuganathan N, Lindsay J, Urbancic K, Ananda-Rajah MR, Chen SC, Bajel A, Ritchie D, Grigg A, Seymour JF, Peleg AY, Kong DC, Slavin MA.

J Antimicrob Chemother. 2016 Dec;71(12):3540-3547. Epub 2016 Aug 11.

PMID:
27521358
30.

Acinetobacter baumannii phenylacetic acid metabolism influences infection outcome through a direct effect on neutrophil chemotaxis.

Bhuiyan MS, Ellett F, Murray GL, Kostoulias X, Cerqueira GM, Schulze KE, Mahamad Maifiah MH, Li J, Creek DJ, Lieschke GJ, Peleg AY.

Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9599-604. doi: 10.1073/pnas.1523116113. Epub 2016 Aug 9.

31.

A Comparative Analysis Between Antibiotic- and Nonantibiotic-Associated Delayed Cutaneous Adverse Drug Reactions.

Trubiano JA, Aung AK, Nguyen M, Fehily SR, Graudins L, Cleland H, Padiglione A, Peleg AY.

J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1187-1193. doi: 10.1016/j.jaip.2016.04.026. Epub 2016 Jun 7.

PMID:
27283055
32.

Anti-infective Surface Coatings: Design and Therapeutic Promise against Device-Associated Infections.

Coad BR, Griesser HJ, Peleg AY, Traven A.

PLoS Pathog. 2016 Jun 2;12(6):e1005598. doi: 10.1371/journal.ppat.1005598. eCollection 2016 Jun. No abstract available.

33.

Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.

Walsh CC, Landersdorfer CB, McIntosh MP, Peleg AY, Hirsch EB, Kirkpatrick CM, Bergen PJ.

J Antimicrob Chemother. 2016 Aug;71(8):2218-29. doi: 10.1093/jac/dkw115. Epub 2016 Apr 26.

PMID:
27118778
34.

Antibiotic regimen based on population analysis of residing persister cells eradicates Staphylococcus epidermidis biofilms.

Yang S, Hay ID, Cameron DR, Speir M, Cui B, Su F, Peleg AY, Lithgow T, Deighton MA, Qu Y.

Sci Rep. 2015 Dec 21;5:18578. doi: 10.1038/srep18578.

35.

Daptomycin-Nonsusceptible Staphylococcus aureus: The Role of Combination Therapy with Daptomycin and Gentamicin.

Jiang JH, Peleg AY.

Genes (Basel). 2015 Nov 30;6(4):1256-67. doi: 10.3390/genes6041256.

36.

Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.

Langan KM, Kotsimbos T, Peleg AY.

Curr Opin Infect Dis. 2015 Dec;28(6):547-56. doi: 10.1097/QCO.0000000000000217. Review. Erratum in: Curr Opin Infect Dis. 2016 Feb;29(1):98.

PMID:
26524327
37.

Impact of a Cross-Kingdom Signaling Molecule of Candida albicans on Acinetobacter baumannii Physiology.

Kostoulias X, Murray GL, Cerqueira GM, Kong JB, Bantun F, Mylonakis E, Khoo CA, Peleg AY.

Antimicrob Agents Chemother. 2015 Oct 19;60(1):161-7. doi: 10.1128/AAC.01540-15. Print 2016 Jan.

38.

Insights on virulence from the complete genome of Staphylococcus capitis.

Cameron DR, Jiang JH, Hassan KA, Elbourne LD, Tuck KL, Paulsen IT, Peleg AY.

Front Microbiol. 2015 Sep 23;6:980. doi: 10.3389/fmicb.2015.00980. eCollection 2015.

39.

Species identification within Acinetobacter calcoaceticus-baumannii complex using MALDI-TOF MS.

Toh BE, Paterson DL, Kamolvit W, Zowawi H, Kvaskoff D, Sidjabat H, Wailan A, Peleg AY, Huber CA.

J Microbiol Methods. 2015 Nov;118:128-32. doi: 10.1016/j.mimet.2015.09.006. Epub 2015 Sep 14.

PMID:
26381662
40.

The influence of bacterial interaction on the virulence of Cryptococcus neoformans.

Dhamgaye S, Murray GL, Peleg AY.

Virulence. 2015;6(7):677-8. doi: 10.1080/21505594.2015.1088632.

41.

Distribution of β-lactamase genes among carbapenem-resistant Klebsiella pneumoniae strains isolated from patients in Turkey.

Iraz M, Özad Düzgün A, Sandallı C, Doymaz MZ, Akkoyunlu Y, Saral A, Peleg AY, Özgümüş OB, Beriş FŞ, Karaoğlu H, Çopur Çiçek A.

Ann Lab Med. 2015 Nov;35(6):595-601. doi: 10.3343/alm.2015.35.6.595.

42.

Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene.

Bæk KT, Thøgersen L, Mogenssen RG, Mellergaard M, Thomsen LE, Petersen A, Skov S, Cameron DR, Peleg AY, Frees D.

Antimicrob Agents Chemother. 2015 Nov;59(11):6983-91. doi: 10.1128/AAC.01303-15. Epub 2015 Aug 31.

43.

Active surveillance for multidrug-resistant Gram-negative bacteria in the intensive care unit.

Abbott IJ, Jenney AW, Spelman DW, Pilcher DV, Sidjabat HE, Richardson LJ, Paterson DL, Peleg AY.

Pathology. 2015 Oct;47(6):575-9. doi: 10.1097/PAT.0000000000000302.

PMID:
26308128
44.

Differentiation of Acinetobacter Genomic Species 13BJ/14TU from Acinetobacter haemolyticus by Use of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS).

Toh BE, Zowawi HM, Krizova L, Paterson DL, Kamolvit W, Peleg AY, Sidjabat H, Nemec A, Pflüger V, Huber CA.

J Clin Microbiol. 2015 Oct;53(10):3384-6. doi: 10.1128/JCM.03468-14. Epub 2015 Jul 29. No abstract available.

45.

In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.

Walsh CC, McIntosh MP, Peleg AY, Kirkpatrick CM, Bergen PJ.

J Antimicrob Chemother. 2015 Nov;70(11):3042-50. doi: 10.1093/jac/dkv221. Epub 2015 Jul 24.

PMID:
26209311
46.

Identification of a Class of Protein ADP-Ribosylating Sirtuins in Microbial Pathogens.

Rack JG, Morra R, Barkauskaite E, Kraehenbuehl R, Ariza A, Qu Y, Ortmayer M, Leidecker O, Cameron DR, Matic I, Peleg AY, Leys D, Traven A, Ahel I.

Mol Cell. 2015 Jul 16;59(2):309-20. doi: 10.1016/j.molcel.2015.06.013. Epub 2015 Jul 9.

47.

Draft Genome Sequences of Clinical Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Strain APS211 and Its Daptomycin-Susceptible Progenitor APS210.

Cameron DR, Jiang JH, Abbott IJ, Spelman DW, Peleg AY.

Genome Announc. 2015 Jun 11;3(3). pii: e00568-15. doi: 10.1128/genomeA.00568-15.

48.

Community-acquired Acinetobacter baumannii: clinical characteristics, epidemiology and pathogenesis.

Dexter C, Murray GL, Paulsen IT, Peleg AY.

Expert Rev Anti Infect Ther. 2015 May;13(5):567-73. doi: 10.1586/14787210.2015.1025055. Review.

PMID:
25850806
49.

Impact of daptomycin resistance on Staphylococcus aureus virulence.

Cameron DR, Mortin LI, Rubio A, Mylonakis E, Moellering RC Jr, Eliopoulos GM, Peleg AY.

Virulence. 2015;6(2):127-31. doi: 10.1080/21505594.2015.1011532.

50.

Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies.

Abbott IJ, Peleg AY.

Semin Respir Crit Care Med. 2015 Feb;36(1):99-110. doi: 10.1055/s-0034-1396929. Epub 2015 Feb 2. Review.

PMID:
25643274

Supplemental Content

Loading ...
Support Center